|
???tair.name??? >
???browser.page.title.author???
|
"oh s c"???jsp.browse.items-by-author.description???
Showing items 1-11 of 11 (1 Page(s) Totally) 1 View [10|25|50] records per page
臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
Showing items 1-11 of 11 (1 Page(s) Totally) 1 View [10|25|50] records per page
|